Platelet count as a prognostic biomarker in resected hepatocellular carcinoma: differential impact of thrombocytosis and thrombocytopenia by btiology and fibrosis.
OpenAlex 토픽 ·
Inflammatory Biomarkers in Disease Prognosis
Hepatocellular Carcinoma Treatment and Prognosis
Venous Thromboembolism Diagnosis and Management
APA
Takashi Matsumoto, Toshiro Masuda, et al. (2026). Platelet count as a prognostic biomarker in resected hepatocellular carcinoma: differential impact of thrombocytosis and thrombocytopenia by btiology and fibrosis.. Surgery today. https://doi.org/10.1007/s00595-026-03303-2
MLA
Takashi Matsumoto, et al.. "Platelet count as a prognostic biomarker in resected hepatocellular carcinoma: differential impact of thrombocytosis and thrombocytopenia by btiology and fibrosis.." Surgery today, 2026.
PMID
42012675
같은 제1저자의 인용 많은 논문 (5)
- Efficacy and safety of nivolumab plus chemotherapy in patients with advanced gastric cancer with massive ascites.
- High γ-H2AX Predicts Clinical Benefit From Platinum-Based Chemotherapy (mFOLFIRINOX) at Recurrence After Pancreatic Cancer Resection.
- A case of dramatic response to pembrolizumab monotherapy in dMMR unresectable colorectal cancer diagnosed following abdominal hemorrhage due to segmental arterial mediolysis.
- Percutaneous aspiration and sclerotherapy for simple hepatic cysts: a systematic review and meta-analysis.
- A randomized controlled phase III trial on continued or paused PD-1 pathway blockade for patients with advanced renal cell carcinoma (JCOG1905, STOP study): a study protocol.